FDA Fast-Tracks TREMFYA for Rare Kids' Diseases with Special Voucher
Published Date: 4/21/2025
Notice
Summary
The FDA just gave the green light to TREMFYA (guselkumab) for a rare pediatric disease, using a special priority review voucher. This means faster approval for treatments that kids with rare diseases really need. The approval happened on March 20, 2025, helping patients get access sooner and encouraging companies to develop more rare disease medicines.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
TREMFYA Approved Using Priority Voucher
The FDA approved TREMFYA (guselkumab) on March 20, 2025, and that approval redeemed a Rare Pediatric Disease Priority Review Voucher. This approval is tied to the rare pediatric disease voucher program and represents an approved treatment for a pediatric indication as of March 20, 2025.
Voucher Program Incentivizes Drug Developers
The FDA issued a Rare Pediatric Disease Priority Review Voucher tied to the TREMFYA approval, reflecting the FD&C Act authority to award such vouchers to sponsors of approved rare pediatric disease products. The notice states the voucher program exists to be awarded and published when redeemed, which can encourage companies to develop rare pediatric disease medicines.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2025-06783 — Determination That MOBIC (Meloxicam) Tablets, 7.5 Milligrams and 15 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA says MOBIC tablets (7.5 mg and 15 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved, so patients and pharmacies won’t face shortages or price jumps. If you use or sell MOBIC, things will keep running smoothly with no surprise changes.
Next: 2025-06785 — Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; AMVUTTRA (vutrisiran)
The FDA just gave the green light to AMVUTTRA (vutrisiran) for a rare kid’s disease, using a special priority review voucher to speed things up. This means faster access to important medicine for families and shows the FDA’s commitment to helping rare pediatric conditions. The approval happened on March 20, 2025, marking a big win for patients and drug developers alike.